Founded in 2010, Shantani Proteome Analytics Pvt. Ltd. is a privately-held biotechnology company that provides novel chemical-proteomics based technologies and services to identify & validate drug targets; thus de-risking molecules and supporting crucial GO / NO-GO decisions throughout the drug discovery process. The company has received SPARSH and SBIRI grant by DBT-BIRAC , GoI. The company has also raised early stage seed capital and angel funding. Shantani is founded by Dr. Chaitanya Saxena who is a seasoned professional and bring successful experience of developing technologies for drug-target deconvolution and drug-target interaction measurements in intact biological systems from his tenure at Eli Lilly & Company. Chaitanya earned a Ph.D. from The Ohio State University, Columbus, OH, USA.
Website: http://shantani.com/